Shanghai AmbioPharm

AmbioPharm is a leading global peptide Contract Development and Manufacturing Organization (CDMO) specializing in the development and cGMP manufacture of peptide-based Active Pharmaceutical Ingredients (APIs). Headquartered in North Augusta, South Carolina, the company operates a major manufacturing and R&D campus in Shanghai, China, which serves as a hub for large-scale production and process optimization. AmbioPharm provides a comprehensive suite of services, including custom peptide synthesis, analytical development, and commercial-scale manufacturing using solid-phase, liquid-phase, and hybrid technologies. The company supports a diverse range of clients in the pharmaceutical and biotechnology sectors, focusing on both New Chemical Entities (NCEs) and a robust portfolio of generic peptide APIs. With recent expansions in both the U.S. and China, AmbioPharm maintains one of the largest peptide manufacturing capacities in the world.